Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein, leading to synaptic loss, neuronal death, and cognitive decline. The pathological accumulation of these proteins begins decades before the manifestation of clinical symptoms, creating a critical window for early detection and intervention. Biomarkers have become essential tools in the diagnosis, monitoring, and research of AD, providing objective measures of underlying disease processes. This article provides a comprehensive overview of the various biomarker categories used in AD research and clinical practice, including fluid, imaging, and genetic biomarkers, along with their clinical applications and validation studies.
The importance of biomarkers in Alzheimer's disease cannot be overstated. Traditional clinical diagnosis based on cognitive assessments alone lacks sensitivity for detecting early-stage disease, and definitive diagnosis historically required postmortem neuropathological examination. The development of biomarker-based diagnostic frameworks has revolutionized the field by enabling in vivo detection of AD pathology, identification of individuals in preclinical stages, and objective monitoring of disease progression and treatment responses[@jack2018].
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein, leading to synaptic loss, neuronal death, and cognitive decline. The pathological accumulation of these proteins begins decades before the manifestation of clinical symptoms, creating a critical window for early detection and intervention. Biomarkers have become essential tools in the diagnosis, monitoring, and research of AD, providing objective measures of underlying disease processes. This article provides a comprehensive overview of the various biomarker categories used in AD research and clinical practice, including fluid, imaging, and genetic biomarkers, along with their clinical applications and validation studies.
The importance of biomarkers in Alzheimer's disease cannot be overstated. Traditional clinical diagnosis based on cognitive assessments alone lacks sensitivity for detecting early-stage disease, and definitive diagnosis historically required postmortem neuropathological examination. The development of biomarker-based diagnostic frameworks has revolutionized the field by enabling in vivo detection of AD pathology, identification of individuals in preclinical stages, and objective monitoring of disease progression and treatment responses[@jack2018].
The ATN framework, introduced by the National Institute on Aging and Alzheimer's Association (NIA-AA), represents a paradigm shift in AD biomarker classification. This framework categorizes biomarkers into three major pathophysiological domains: A (Amyloid), T (Tau/neurodegeneration), and N (Neurodegeneration/neuronal injury)[@jack2016]. The ATN system provides a biomarker-based definition of AD that is independent of clinical symptoms, allowing for the identification of individuals with amyloid-positive, tau-positive, and neurodegeneration-positive profiles who may or may not yet exhibit cognitive impairment. This framework has become the standard for research criteria and clinical trial enrichment strategies[@jack2013].
Clinical significance of biomarkers extends beyond diagnosis to include risk stratification, disease monitoring, and therapeutic development. Biomarkers enable the identification of individuals at highest risk for progression, allow tracking of pathological changes over time, and serve as surrogate endpoints in clinical trials. The integration of biomarkers into clinical practice has improved diagnostic accuracy and enabled earlier intervention, potentially allowing for disease modification before irreversible neuronal loss occurs[@solomon2015].
Amyloid-beta 42 (Aβ42) and amyloid-beta 40 (Aβ40) are the most extensively studied amyloid biomarkers in cerebrospinal fluid (CSF). Aβ42, the more aggregation-prone isoform, is the principal component of amyloid plaques. In AD, CSF Aβ42 levels are characteristically reduced due to sequestration of the peptide into plaques in the brain, reflecting the underlying amyloid pathology[@blennow2016]. The Aβ42/Aβ40 ratio has emerged as a more reliable indicator than absolute Aβ42 values, as it corrects for inter-individual variations in total Aβ production and provides improved diagnostic accuracy for identifying amyloid positivity[@janelidze2018].
Amyloid-beta oligomers represent the most toxic species of Aβ, functioning as soluble synaptic toxins that precede plaque formation. These oligomers correlate strongly with cognitive impairment and are considered superior to plaque burden for predicting cognitive decline. Studies have demonstrated that CSF Aβ oligomers can distinguish AD patients from controls with high sensitivity and specificity, and are associated with synaptic loss measured by neuroimaging[@hong2022].
The amyloid precursor protein (APP) is a transmembrane protein that undergoes proteolytic processing by secretases to produce Aβ peptides. Beta-site APP-cleaving enzyme 1 (BACE1) is the rate-limiting enzyme responsible for the initial cleavage of APP to generate the C-terminal fragment that subsequently yields Aβ. BACE1 activity in CSF has been investigated as a biomarker, with elevated levels observed in early AD, reflecting increased amyloidogenic processing[@zhou2012]. However, BACE1 inhibitors developed as therapeutic agents have shown significant adverse effects, highlighting the complexity of targeting this pathway.
Gamma-secretase is the enzyme complex responsible for the final cleavage of APP to release Aβ peptides. While gamma-secretase modulators have been explored as therapeutic agents, measuring gamma-secretase activity directly in vivo remains challenging. The ratio of Aβ42 to Aβ40 production serves as a functional readout of gamma-secretase activity, with altered ratios suggesting changes in enzyme processing[@haass2009].
Pittsburgh compound B (PiB) was the first widely adopted amyloid PET tracer, enabling in vivo visualization of amyloid plaques. PiB-PET demonstrates high sensitivity for detecting cerebral amyloid angiopathy and neuritic plaques, with good correlation with postmortem amyloid burden. Studies have validated PiB retention as a biomarker for amyloid pathology, showing excellent discrimination between AD patients and cognitively normal controls[@klunk2004].
Florbetapir (F18-AV-45) received FDA approval for amyloid PET imaging, providing a clinically usable tool for amyloid detection. Florbetapir binding shows strong correlation with postmortem plaque density and demonstrates good test-retest reliability. The tracer has been validated in multiple large-scale studies and is now commonly used in clinical settings for amyloid confirmation[@wong2010].
Total tau (t-tau) in CSF reflects neuronal damage and axonal degeneration. Elevated t-tau levels are observed in AD compared to controls and other dementias, making it a sensitive marker of neurodegeneration. Meta-analyses have demonstrated that t-tau can distinguish AD from frontotemporal dementia and other neurodegenerative conditions with moderate accuracy[@blennow2000]. Importantly, t-tau levels predict rate of cognitive decline and brain atrophy, serving as a prognostic biomarker.
Phosphorylated tau (p-tau) isoforms provide disease-specific information about tau pathology. p-tau181 was the first extensively validated p-tau species, demonstrating high specificity for AD compared to other neurodegenerative disorders. p-tau181 reflects the presence of neurofibrillary tangles and shows strong correlation with tau PET signal[@schll2016].
p-tau217 has emerged as one of the most promising tau biomarkers, demonstrating superior performance compared to other p-tau isoforms. Studies have shown that p-tau217 can detect tau pathology even in preclinical stages, accurately differentiate AD from other tauopathies, and predict progression from mild cognitive impairment to AD[@barthlemy2020]. The Minnesota cohort study demonstrated that p-tau217 in CSF identified individuals with tau pathology with high accuracy up to 20 years before clinical symptoms[@palmqvist2020].
p-tau231 reflects early tau pathology and shows promise for detecting changes in preclinical AD. This isoform may be particularly useful for tracking disease progression in early stages, as p-tau231 levels correlate with memory performance in cognitively normal individuals with amyloid positivity[@moscoso2021].
Flortaucipir (F18-AV-1451, also known as T807) is the most extensively validated tau PET tracer, designed to bind to neurofibrillary tangles. Flortaucipir PET demonstrates regional binding patterns that closely mirror the distribution of neurofibrillary pathology in AD, with ligand retention in temporal and parietal regions correlating with cognitive impairment[@xia2013]. Studies have validated flortaucipir uptake as a marker of tau pathology, showing good agreement with CSF p-tau measures and postmortem data.
PI-2620 is a second-generation tau PET tracer with improved pharmacokinetic properties. PI-2620 shows specific binding to tau aggregates in AD and has demonstrated utility in detecting both early and advanced tau pathology. Comparative studies suggest PI-2620 may provide advantages for detecting off-target binding issues seen with first-generation tracers[@kroth2019].
Neurofilament light chain (NfL) is a promising biomarker of axonal damage. CSF and blood NfL levels are elevated in AD and correlate with disease severity and progression. Studies have demonstrated that NfL can predict conversion from mild cognitive impairment to AD and track disease progression over time[@zetterberg2019]. The development of ultra-sensitive assay platforms has enabled reliable measurement of NfL in blood, facilitating large-scale screening and monitoring applications.
Neuron-specific enolase (NSE) is a cytosolic enzyme predominantly localized in neurons. Elevated CSF NSE has been reported in AD and correlates with cognitive decline. However, NSE lacks specificity for AD, as elevated levels are also observed in other neurological conditions[@parnetti2000].
Microtubule-associated protein 2 (MAP2) is a neuronal cytoskeletal protein that serves as a marker of dendritic integrity. Decreased CSF MAP2 reflects dendritic damage and synaptic loss in AD. Studies have demonstrated associations between MAP2 levels and cognitive performance, suggesting utility as a marker of synaptic pathology[@schnknecht2002].
Synaptic dysfunction represents an early event in AD pathogenesis, and synaptic biomarkers provide important information about disease progression. Synaptophysin, synaptotagmin, and SNAP-25 are among the synaptic proteins measured in CSF as markers of synaptic integrity. These biomarkers show reductions in AD and correlate with cognitive deficits, providing additional information beyond amyloid and tau measures[@ting2016].
Neuroinflammation plays a crucial role in AD pathogenesis, with microglial activation and inflammatory responses contributing to disease progression. Interleukin-6 (IL-6) is a pro-inflammatory cytokine elevated in AD CSF and blood. IL-6 levels correlate with disease severity and have been associated with increased risk of incident dementia in longitudinal studies[@baggio2013].
Tumor necrosis factor-alpha (TNF-α) is another key inflammatory mediator elevated in AD. TNF-α levels are associated with cognitive decline and brain atrophy, suggesting involvement in disease pathogenesis. Studies have explored anti-inflammatory interventions targeting these pathways, though with limited success to date.
Glial fibrillary acidic protein (GFAP) is an astrocyte-specific intermediate filament protein. Blood GFAP levels are elevated in AD and reflect astrocyte activation. Importantly, GFAP shows promise as a blood biomarker that increases in parallel with amyloid pathology and may provide information complementary to neuronal injury markers[@chatterjee2021].
YKL-40 (also known as chitinase-3-like protein 1) is a chitinase protein produced by activated microglia and astrocytes. CSF YKL-40 is elevated in AD and predicts progression from mild cognitive impairment to AD. This biomarker provides information about neuroinflammatory processes not captured by amyloid or tau measures[@baldacci2015].
Microglial activation can be imaged using PK11195 PET, a translocator protein (TSPO) ligand. Studies have demonstrated increased PK11195 binding in AD brain regions, correlating with cognitive impairment and providing in vivo evidence of microglial activation in AD pathogenesis[@edison2008].
CSF remains the primary source for AD biomarker analysis, providing direct access to brain-derived proteins. The core CSF biomarker panel for AD includes Aβ42, t-tau, and p-tau, which together provide information about amyloid, neurodegeneration, and tau pathology. This panel has been validated in numerous studies and is incorporated into diagnostic criteria for AD[@shaw2009].
The Aβ42/Aβ40 ratio has largely replaced single Aβ42 measurements in clinical practice due to improved diagnostic performance. Studies comparing CSF biomarkers with neuropathology have demonstrated that the Aβ42/Aβ40 ratio accurately identifies individuals with significant amyloid pathology at autopsy[@irving2018].
The development of ultra-sensitive immunoassays has enabled reliable measurement of brain-derived proteins in blood, revolutionizing AD biomarker research. Blood p-tau181 has demonstrated excellent performance for detecting AD pathology, with levels correlating strongly with CSF p-tau181 and amyloid PET positivity. Studies have shown that blood p-tau181 can distinguish AD from other neurodegenerative disorders with high accuracy[@janelidze2020].
Blood p-tau217 shows even greater promise, with performance matching or exceeding that of CSF biomarkers in some studies. Blood p-tau217 demonstrates superior ability to detect early AD pathology and may be particularly useful for screening and population-based studies[@karikari2020].
Blood NfL has emerged as a sensitive marker of neurodegeneration that can be measured reliably using single-molecule array (Simoa) technology. Blood NfL correlates with disease progression and brain atrophy, providing prognostic information useful for clinical trials and patient management[@khalil2018].
Blood GFAP shows promise as an astrocyte activation marker that increases with amyloid pathology. Studies have demonstrated that blood GFAP accurately identifies amyloid-positive individuals and may provide information about disease stage and progression[@oeckl2022].
Method comparison studies have shown strong correlation between blood and CSF biomarkers for p-tau and NfL, validating blood-based testing as a less invasive alternative to lumbar puncture. However, some biomarkers show better concordance than others, and optimal implementation strategies continue to be evaluated.
Structural magnetic resonance imaging (MRI) provides measures of brain atrophy, particularly in medial temporal lobe structures including the hippocampus and entorhinal cortex. Hippocampal atrophy on MRI is a characteristic finding in AD and correlates with memory impairment. MRI-based volumetric measurements are widely used in clinical trials as endpoints and in diagnostic evaluation to support AD diagnosis[@frisoni2010].
Fluorodeoxyglucose (FDG) positron emission tomography (PET) measures cerebral glucose metabolism, revealing hypometabolism in AD-typical regions including the posterior cingulate, precuneus, and temporoparietal cortex. FDG-PET can distinguish AD from frontotemporal dementia and provides prognostic information about risk of progression in mild cognitive impairment[@minoshima1995].
Diffusion tensor imaging (DTI) provides information about white matter integrity by measuring water diffusion characteristics. DTI reveals white matter damage in AD that correlates with cognitive impairment. Studies have demonstrated that DTI metrics can detect changes in preclinical AD and may provide information complementary to volumetric measurements[@nir2015].
Resting-state functional MRI (rsfMRI) measures intrinsic brain connectivity, revealing disruption of functional networks in AD. Default mode network connectivity is particularly affected, with alterations observed even in preclinical stages. rsfMRI may provide biomarkers for early detection and monitoring of functional network changes[@greicius2004].
Apolipoprotein E (APOE) is the most significant genetic risk factor for late-onset AD. The ε4 allele increases risk approximately 3-4 fold in heterozygotes and 12-15 fold in homozygotes, while the ε2 allele is protective. APOE genotyping provides important information about risk stratification and is increasingly used in clinical practice for counseling and in clinical trials for enrichment strategies[@liu2013].
Mutations in APP, PSEN1, and PSEN2 cause autosomal dominant familial AD. Genetic testing for these genes is indicated for individuals with early-onset AD or a strong family history. Identification of pathogenic mutations enables definitive diagnosis and allows for predictive testing in at-risk family members. These mutations are associated with high penetrance and typically lead to early-onset disease[@ryman2018].
Genome-wide association studies have identified numerous AD risk loci, including CLU, PICALM, CR1, and TREM2. The TREM2 variants associated with increased AD risk highlight the importance of microglia in disease pathogenesis. While individual genetic risk scores have limited clinical utility, polygenic risk scores combining multiple variants show promise for improving risk stratification[@karch2014].
The integration of multiple biomarkers provides superior diagnostic accuracy compared to individual markers. Studies have demonstrated that combining amyloid, tau, and neurodegeneration biomarkers achieves sensitivity and specificity exceeding 90% for AD diagnosis. The optimal combination depends on the clinical context, with some applications requiring maximum specificity while others prioritize early detection[@hansson2019].
The ATN framework has been operationalized in large research studies including the Alzheimer's Disease Neuroimaging Initiative (ADNI). Studies implementing ATN classification have demonstrated that biomarker profiles can successfully categorize individuals according to pathophysiological stage and predict progression. The framework enables a research framework for AD that is biologically based rather than solely clinically defined[@veitch2019].
Biomarkers enable identification of AD pathology in individuals with subjective cognitive decline or mild cognitive impairment before the development of overt dementia. Early diagnosis allows for timely intervention, planning, and access to emerging disease-modifying therapies. Biomarker-based early detection is particularly important given the anticipated approval of amyloid-targeting therapies that may be most effective in early disease stages[@dubois2016].
Biomarkers play an increasingly important role in distinguishing AD from other neurodegenerative disorders. The combination of amyloid and tau biomarkers allows differentiation of AD from frontotemporal lobar degeneration, Lewy body disease, and vascular dementia. Specific patterns of neurodegeneration and inflammatory markers provide additional diagnostic information[@ossenkoppele2015].
Biomarkers serve as critical endpoints in AD clinical trials, enabling detection of drug effects on underlying pathology. Amyloid PET, tau PET, and fluid biomarkers are used to demonstrate target engagement, biological activity, and disease modification. Biomarker-based enrichment strategies improve trial efficiency by identifying individuals most likely to show progression[@fda2018].
Longitudinal biomarker measurements provide objective measures of disease progression. Changes in amyloid and tau biomarkers over time reflect biological disease activity, while neurodegeneration markers track downstream effects. Biomarker monitoring may enable individualized treatment decisions and adjustment of therapeutic strategies based on objective measures of response[@oconnor2019].
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: